Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA plasmids

            Therapeutic Area: Neurology Product Name: CG01

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: CombiGene AB

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 13, 2020

            Details:

            Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CG01

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2020

            Details:

            Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.